The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation
Open accessAbstract
Colorectal cancer (CRC) growth and progression is frequently driven by RAS pathway activation through upstream growth factor receptor activation or through mutational activation of KRAS or BRAF. Here we describe an additional mechanism by which the RAS pathway may be modulated in CRC. PTPRS, a receptor-type protein tyrosine phosphatase, appears to regulate RAS pathway activation through ERK. PTPRS modulates ERK phosphorylation and subsequent translocation to the nucleus. Native mutations in PTPRS, present in ~10% of CRC, may reduce its phosphatase activity while increasing ERK activation and downstream transcriptional signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 ERK targeted gene regulation and specific phosphorylations. The CRC cell lines SW620, KM12L4A, HCT116 (WT KRAS) [HCT116 (−/+)], and HCT116 [HCT116 (KRAS G13D/+)] along with their paired CRISPR PTPRS knockout cell lines were grown and cell extracts were prepared. Western blot analysis for Phospho-p90RSK (Ser 380), DUSP6, and C-Myc were performed. The PTPRS knockout cell line in each pair shows the presence of more protein for each product tested than its parental matching cell line. This effect is consistent even between the WT KRAS and mutant KRAS HCT116 cells. Phosphorylation of Elk-1 (S383) and MSK1 (T581) are shown. Quantitations were determined by normalizing the phosphorylated protein values with the total protein; then dividing the PTPRS KO by the CRISPR control values. The mean and standard deviation are shown.](https://figures.cochat.ai/paper-figures/75d829a770d84ac4bf59252f130d76f2/ptprs-regulates-colorectal-cancer-ras-pathway-activity-by-inactivating-erk-and-figure-5.jpg)
![Figure 6 The activation of EGFR and ERK in PTPRS knockout cell lines and in response to EGF stimulation. (a) The CRC PTPRS CRISPR KO cell lines SW620, KM12L4A, HCT116 [mutant KRAS G13D/+], and HCT116 [WT KRAS −/+] and their CRISPR control cells were cultured, and harvested for western blotting to determine the phosphorylation of EGFR. Phosphorylation of EGFR Y1173, Y1068 and total EGFR are shown. Quantitations were done normalizing each phospho-EGFR levels against total EGFR levels; normalized phospho-EGFR values for the KO were then divided by the control values to see the fold change difference. SW620 shows no EGFR expression revealing that EGFR appears to be not the driving mechanism of the observed change in phospho-ERK. HCT116 [KRAS G13D/+] also shows no change in EGFR phosphorylation. The WT KRAS cell lines, KM12L4A and HCT116 [WT KRAS −/+] do show a change in phospho-EGFR. All experiments were done in triplicate. The mean and standard deviation are shown. Two-tailed, paired t test was used to determine the statistical significance for comparison as indicated. (b) Time course of serum starved HCT116 parental [mutant KRAS, G13D/+] PTPRS CRISPR KO and CRISPR control cells treated with EGF (50 ng/ml). At the times indicated, cells were harvested and extracts were prepared for western blotting. EGFR, EGFR phosphorylated at Y1173 andY1068, as well as ERK, phospho-ERK, AKT and phospho-AKT are shown. (c) HCT116 WT KRAS [−/+] PTPRS CRISPR KO and CRISPR control cells are shown with identical treatment as in (b). (d) This graph shows the normalized values of phospho-EGFR (left panels, average of Y1173 and Y1068), phospho-ERK (middle panels), and phospho-AKT (right panels) for the blots shown in Fig. 6b (top three panels) and Fig. 6c (bottom three panels). All experiments were done in triplicate. The mean and standard deviation are shown. Two-tailed, paired t test was used to determine the statistical significance for comparison. Significant P values (<0.05) are shown; * − near significant P values.](https://figures.cochat.ai/paper-figures/77a04d74215741c2923b0c1d4c695eca/ptprs-regulates-colorectal-cancer-ras-pathway-activity-by-inactivating-erk-and-figure-6.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“We previously reported that PTPRS negatively regulated ERK activity in CRC cells [34].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [34]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“suggesting these tumors may have non-canonical RAS pathway activation (e.g. through phosphatases such as PTPRS [34]) and may be candidates for MEKi treatment.”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Molecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Allegra, C. J., Jessup, J. M., Somerfield, M. R., Hamilton, S. R., Hammond, E. H., Hayes, D. F., McAllister, P. K., Morton, R. F., & Schilsky, R. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9170 · Cited by 1,156
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913
Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887
Cited by
Leung, K. K., Wilson, G. M., Kirkemo, L. L., Riley, N. M., Coon, J. J., & Wells, J. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917947117 · Cited by 83
Secreted ADAMTS-like proteins as regulators of connective tissue function
Taye, N., Redhead, C., & Hubmacher, D. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00680.2023 · Cited by 26
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
“Striking correlation of MEKi resistance with SRC activation in 2250 CRCs We previously reported that PTPRS negatively regulated ERK activity in CRC cells [34].”
BackgroundInfluentialSelf-citationRepurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Yang, M., Schell, M. J., Loboda, A. P., Nebozhyn, M., Li, J., Teer, J. K., Pledger, W. J., & Yeatman, T. J. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1383 · Cited by 23
Self-citationThe role of receptor‐type protein tyrosine phosphatases in cancer
Lv, Z., Wang, T., Cao, X., Sun, M., & Qu, Y. (2023) · Precision Medical Sciences · doi:10.1002/prm2.12090 · Cited by 21
Metadata
- Authors
- Davis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- Venue
- Scientific Reports
- Published
- 2018-06-18
- Volume
- 8
- Issue
- 1
- Pages
- 9296-9296
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC6006154
- OpenAlex
- W2808489475
- Cited by
- 27
- References
- 61
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (U01CA157960, P30CA076292)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- PTPRS, colorectal cancer, Ras signaling, ERK1/2 phosphorylation, ERK nuclear translocation, receptor-type protein tyrosine phosphatase, KRAS, BRAF
- MeSH terms
- Cell Nucleus, Enzyme Activation, Humans, Mutation, Phosphorylation, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, ras Proteins, Mitogen-Activated Protein Kinase Kinases, Protein Transport, RNA, Small Interfering, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins c-akt, Receptor-Like Protein Tyrosine Phosphatases, Class 2, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. https://app.cochat.ai/papers/10.1038/s41598-018-27584-x
- The paper
- Davis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018). PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation. Scientific Reports. https://doi.org/10.1038/s41598-018-27584-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.